|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||56.30 - 58.27|
|52 Week Range||24.00 - 116.12|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||5.09|
|Expense Ratio (net)||1.12%|
With markets still rebounding from late-2018’s sell-off and first-quarter earnings quickly approaching, we thought it would be a good time to take a look at which thematic ETFs among Direxion’s leveraged catalog have so far shown the strongest results on the year. Past performance is not indicative of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.
The Zacks Analyst Blog Highlights: Direxion Daily S&P, Direxion Daily Regional Banks, Direxion Daily Aerospace, Direxion Daily Industrials and Direxion Daily Small Cap
We have highlighted six leveraged ETFs that have piled up exceptional returns in the first month of 2019 given that Wall Street made a sharp turnaround, posting the best month in many decades.
Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.
We have highlighted nine ETFs that have piled up exceptional returns to start 2019 and will continue to be investors' darlings provided the sentiments remain the same.
Biotechnology stocks and the related exchange traded funds are off to sizzling starts in 2019. The soaring start to 2019 by the equal-weight S&P Biotechnology Select Industry Index is lifting the fortunes of the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). LABU, one of the largest leveraged biotechnology ETFs, is up more than 45 percent year-to-date, easily making it ne of Direxion's best-performing leveraged bullish ETFs in the month of January.
According to a report by the Silicon Valley Bank, biopharma deals in 2018 totaled $49 billion and more mergers in 2019 could continue providing growth in the industry, fueling ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) . This was evident early in the new year as the biopharma space began 2019 with Bristol-Myers Squibb offering $74 billion to take over Celgene--a deal that could allow Bristol to become a top five pharmaceutical giant. RBC Capital Markets analyst Brian Abrahams said there's "a strong need to diversify around maturing franchises with (patents expiring) and biotech valuations having come down.
Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday's midterm elections, Democrats emerged with control of the House while Republicans maintained control of the Senate. Among the winning exchange traded funds Wednesday were biotechnology funds, including the SPDR S&P Biotech ETF (XBI) , which takes an equal-weight approach to the biotech space.
Biotechnology stocks and exchange traded funds participated in the October broader market swoon, punishing funds such as the Direxion Daily S&P Biotech Bull Shares (LABU) in the process. LABU, which takes the 3x or 300% daily performance of the S&P Biotechnology Select Industry Index, is attempting to reverse its October slide this month and is off to a good start with a November gain of about 14%. The slump in once hot biotechnology ETFs could present investors with a buying opportunity.
Few asset classes are as seductive as leveraged exchange-traded funds (ETFs). Other than leveraged ETFs, where else in the fund universe (without using options) can investors make a bet on a simple index, such as the S&P 500 or Nasdaq-100 Index, and amplify those benchmarks’ gains to the tune of 200% or even 300% in a single trading day?
Usually, when investors add biotechnology stocks to their portfolios, they feel confident about risk. When they want to reduce risk, biotech names are the first to go. LABU (3X Biotech Bull) and LABD (3X Biotech Bear) can help you stay risk-on or risk-off.
Many institutional traders use multi-faceted strategies that involve several different instruments when trading around an earnings report. Among the most common hedging tools used by institutions are leveraged ETFs, which are built to deliver multiples (or inverse multiples) on a given index. “They aren’t meant to be held for more than a few days at a time,” Sylvia Jablonski, managing director of leveraged ETF provider Direxion ETFs said.
The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few factors spurning the growth in the biotechnology and pharmaceuticals industry, giving ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) exceptional returns. PILL seeks investment results equal to 300% of the daily performance of the Dynamic Pharmaceutical Intellidex Index and concentrates its allocations towards securities of the index and other financial instruments that provide daily leveraged exposure to the index. The index itself just matched a previous high and PILL itself is posting year-to-date returns of 6.36% according to performance figures from Yahoo! Finance.
Since 1997, Direxion has been providing investment solutions with their innovative ETFs and 20 years later, they have $13.4 billion worth of assets under management. If you haven't already, check out the 5 ETFs below that are trending this week - and are worth keeping an eye on during the second half of 2018. Despite all the talk regarding trade wars with the United States and China, one sector that has been shrugging off the market noise is the biotechnology sector.
Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.
Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech ETF (NYSEArca: XBI) came into Monday with a loss of almost 12.6% over the past ...